Abstract
Pharmacophore models of G protein-coupled receptor40 (GPR40) agonists were developed using Discovery Studio V2.1. One hydrogen bond acceptor and three hydrophobic features, Hypo 1 which was the best hypothesis, had a correlation co-efficient of 0.971, cost difference of 73.041, and RMSD 0.680. This model was validated by test set, Fischer randomization test and decoy set. Subsequently, Hypo 1 was employed as a 3D query to identify potent molecules from chembridge database. 21 compounds were identified with estimated EC50 less than 500 nM. Seven top-scored hit compounds were chosen for further evaluation in FLIPR assay and two compounds were discovered as potent GPR40 agonists.
Keywords: 3D-QSAR-pharmacophore, discovery studio, GPR40 agonists, HypoGen, virtual screening.
Current Computer-Aided Drug Design
Title:3D-QSAR Based Pharmacophore Modeling and Virtual Screening for Identification of Novel G Protein-Coupled Receptor40 Agonists
Volume: 11 Issue: 1
Author(s): Peng Lu, Yubin Wang, Ping Kai Ouyang, Jinxiong She and Mingfang He
Affiliation:
Keywords: 3D-QSAR-pharmacophore, discovery studio, GPR40 agonists, HypoGen, virtual screening.
Abstract: Pharmacophore models of G protein-coupled receptor40 (GPR40) agonists were developed using Discovery Studio V2.1. One hydrogen bond acceptor and three hydrophobic features, Hypo 1 which was the best hypothesis, had a correlation co-efficient of 0.971, cost difference of 73.041, and RMSD 0.680. This model was validated by test set, Fischer randomization test and decoy set. Subsequently, Hypo 1 was employed as a 3D query to identify potent molecules from chembridge database. 21 compounds were identified with estimated EC50 less than 500 nM. Seven top-scored hit compounds were chosen for further evaluation in FLIPR assay and two compounds were discovered as potent GPR40 agonists.
Export Options
About this article
Cite this article as:
Lu Peng, Wang Yubin, Ouyang Kai Ping, She Jinxiong and He Mingfang, 3D-QSAR Based Pharmacophore Modeling and Virtual Screening for Identification of Novel G Protein-Coupled Receptor40 Agonists, Current Computer-Aided Drug Design 2015; 11 (1) . https://dx.doi.org/10.2174/1573409911666150529125814
DOI https://dx.doi.org/10.2174/1573409911666150529125814 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in the Search for Biomarkers for the Diagnosis and Monitoring of Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells
Current Stem Cell Research & Therapy When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Current Signal Transduction Therapy Synthetic Molecules that Modulate Transcription and Differentiation: Hints for Future Drug Discovery
Combinatorial Chemistry & High Throughput Screening Biology of Mesenchymal Stem Cells
Current Rheumatology Reviews System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) First Phase Insulin Secretion and Type 2 Diabetes
Current Molecular Medicine Possibilities of Non-Viral Gene Transfer to Improve Cutaneous Wound Healing
Current Gene Therapy Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Intraductal Papillary Mucinous Neoplasm (IPMN): A Precursor to Pancreatic Cancer
Current Cancer Therapy Reviews Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity
Recent Patents on Cardiovascular Drug Discovery Functions of S100 Proteins
Current Molecular Medicine Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Drug-induced Cholelithiasis
Current Reviews in Clinical and Experimental Pharmacology Modelling and Treating Amyotrophic Lateral Sclerosis through Induced- Pluripotent Stem Cells Technology
Current Stem Cell Research & Therapy Mechanisms of CTLA-4-Ig in Tolerance Induction
Current Pharmaceutical Design Does in vitro Fertilisation Increase Type 2 Diabetes and Cardiovascular Risk?
Current Diabetes Reviews